G1 Pharma (GTHX) Net earnings per share growth forecast for next year

Corporate company logo of G1 Therapeutics (GTHX)

G1 Therapeutics, Inc. (GTHX) relies on outsourced manufacturing in the US and is implementing eco-friendly water purification cycles. The current trajectory of next year's EPS forecasts visualizes the impact of these factors, where the 158.70 metric indicates the status of expected returns. FDA patents and the integration of drugs into medical protocols ensure business resilience, creating significant barriers to entry for competitors.

G1 Pharma (GTHX): Net earnings per share growth forecast for next year from 07/04/2022 to 09/28/2024

Summary analytical data breakdowns for G1 Therapeutics, Inc. (GTHX)

- share price and consensus valuation forecast:
Fundamental company analysis:G1 Therapeutics Inc.
Finished products of G1 Pharma

The selection of defensive assets is based on the stability of cash flows, which for G1 Therapeutics, Inc. (GTHX) is ensured by a royalty model from pharma behemoths for molecule licensing. This forward earnings per share valuation history aggregates analyst consensus forecasts for EPS dynamics, allowing investors to assess fundamental growth potential and identify microstructural imbalances between market expectations and macroeconomic risks.

Competitor analysis for G1 Therapeutics, Inc.

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year canfite.com (CANF)|Net earnings per share growth forecast for next year aprea.com|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year SLXN|Earnings growth forecast for next year NuCana PLC (NCNA)|Net earnings per share growth forecast for next year Chimerix, Inc CMRX|CYCC (Cyclacel) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)